N@N

GERN, UTHR, OMCL, FCN, SO, MPWR, Expected to Trade Lower After Bearish Insider Trading

^{Published on 2011-06-20 09:00:21 - WOPRAI}
 

June 20, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Lower in the next 6 months. GERON CORPORATION (NASDAQ:GERN), UNITED THERAPEUTICS CORPORATION (NASDAQ:UTHR), OMNICELL INCORPORATED (NASDAQ:OMCL), FTI CONSULTING, INC. (NYSE:FCN), SOUTHERN COMPANY (THE) (NYSE:SO), MONOLITHIC POWER SYSTEMS, INC. (NASDAQ:MPWR) are all expected to go Lower as Sell signals have been generated by top insider trading patterns. The most important data elements considered when performing insider analysis are: Insiders Track Record - An insiders track record is best summarized by the Insider Score which ranges from 1 (least predictive) to 100 (most predictive) based on prior trading performance. In addition, the actual returns following the insiders prior trades are included to determine the potential magnitude of future returns. Insiders Role - Trades by higher-level insiders are generally more predictive than trades by lower level insiders. Higher-level insiders to include Chairman (CB), Chief Executive Officer (CEO), President (P), Chief Financial Officer (CFO), and Vice Chairman (VC).

The chart below displays the stocks expected to go Lower along with the insider name, position, predictive insider score, 6 month expected return and number of trading decisions included in the score.

     Symbol     Company Name                        Insider Name                        Role        Shares         Insider Score     Avg 6 Month Return     # of Dec. 
     GERN       GERON CORPORATION                   Greenwood, David L                  CEO         34,005         99                -13.2%                 20        
     UTHR       UNITED THERAPEUTICS CORPORATION     Ferrari, John Maxim                 CFO         5,500          90                -5.3%                  41        
     OMCL       OMNICELL INCORPORATED               Lindholm, Randy D                   D           8,555          82                -29.0%                 7         
     FCN        FTI CONSULTING, INC.                Callaghan, Denis J                  D           5,625          75                -2.7%                  27        
     SO         SOUTHERN COMPANY (THE)              Hinson, W Ron                       O           11,197         79                -14.8%                 4         
     MPWR       MONOLITHIC POWER SYSTEMS, INC.      Ueunten, Paul                       O           13,000         75                -9.3%                  20        

GERON CORPORATION (NASDAQ:GERN) - Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. It develops a range of anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines; and diagnostics based on telomerase detection, as well as intends to develop products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. The company develops Imetelstat (GRN163L), which is in Phase I clinical trial for the treatment of chronic lymphoproliferative diseases, solid tumors, multiple myeloma, and non-small cell lung cancer. GRN163L is also in Phase I/II clinical trial to treat breast cancer. The company also develops GRNVAC1 that is in Phase II clinical trial for the treatment of acute myelogenous leukemia. It also develops GRNOPC1, which is in Phase I Trial for treatment of spinal cord injury; and GRNCM1 that is in preclinical stage to treat heart disease and screening. The company has licensing agreement with Merck & Co. to develop telomerase cancer vaccine, which is in Phase I clinical trial for the treatment of prostate and solid tumors; Sienna Cancer Diagnostics to develop a preclinical stage product for the treatment of bladder cancer; and has a collaboration with the University Campus Suffolk to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

UNITED THERAPEUTICS CORPORATION (NASDAQ:UTHR) - United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. It offers Remodulin, Tyvaso, and Adcirca (tadalafil) tablets for the treatment of pulmonary arterial hypertension (PAH); and CardioPAL SAVI and decipher cardiac monitors, and CardioPAL SAVI wireless cardiac event monitors for cardiac arrhythmias and ischemic heart disease. The companys under development products include Oral Treprostinil, which is in Phase III clinical trials for the treatment of PAH and is in Phase II clinical trials for the treatment of peripheral vascular disease; Beraprost-MR, a Phase II clinical trials product for the treatment of PAH; 3F8 MAb, a Phase II clinical trials product for neuroblastoma; Aviptadil, a Phase II clinical trials product targeting pulmonary hypertension and other pulmonary diseases; 8H9 MAb, a Phase I clinical trials product for the treatment of metastatic brain cancer; IW001, a Phase I clinical trials product that targets idiopathic pulmonary fibrosis and primary graft dysfunction; and Glycobiology Antiviral Agents, which are in pre-clinical trials for Hepatitis C and other infectious diseases. United Therapeutics Corporation also provides telemedicine monitoring services to detect cardiac arrhythmias and ischemic heart disease. The company sells its products through sales and marketing staff, specialty pharmaceutical distributors, and pharmaceutical wholesalers. It has a licensing agreements and relationships with Eli Lilly and Company; Toray Industries, Inc.; NEBU-TEC; Mondobiotech; ImmuneWorks; GlaxoSmithKline PLC; Pfizer Inc.; and Supernus Pharmaceuticals, Inc. The company was formerly known as Lung Rx, Inc. and changed its name in December, 1997. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

OMNICELL INCORPORATED (NASDAQ:OMCL) - Omnicell, Inc. develops, markets, sells, and supports medication and supply dispensing systems to the healthcare industry primarily in the United States and Canada. Its products include OmniRx dispensing system that automates the management and dispensing of medications at the point of use; Mobile Carts, a mobile wireless computer and dispensing system that allows medication control to be taken to the bedside and provides a platform for other hospital information systems; and SinglePointe, a software product that is used to control medications on a patient-specific basis. The company also offers OmniLinkRx, a software product that automates communication between nurses and the pharmacy; WorkflowRx, an automated storage, retrieval, and repackaging solution for the central pharmacy; SecureVault, a controlled substance barcode inventory management system; SafetyMed, a mobile nursing workflow automation and barcode medication administration system; and Anesthesia Workstation, a mobile system for the management of anesthesia supplies and medications. Its medication and surgical supply products include Omnicell Supply Solution that dispenses and tracks medical and surgical supplies at the point of use; Supply/Rx Combination Solution, which is designed to manage medications and supplies in one versatile cabinet or group of cabinets; Omnicell Tissue Center; OptiFlex SS for the perioperative areas; and OptiFlex CL for the cardiac catheterization lab and other procedure areas. In addition, Omnicell provides customer education and training, maintenance and support, post-installation, technical support, and onsite services; Omnicell Interface Software; and professional services. The company also sells its products through distributors in Asia, Australia, Europe, the Middle East, and South America. It was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was founded in 1992 and is headquartered in Mountain View, California.

FTI CONSULTING, INC. (NYSE:FCN) - FTI Consulting, Inc. operates as a business advisory company worldwide. The company operates in five segments: Corporate Finance/Restructuring, Forensic and Litigation Consulting, Economic Consulting, Technology, and Strategic Communications. The Corporate Finance/Restructuring segment focuses on strategic, operational, financial, and capital needs of businesses. This segment provides consulting and advisory services on a range of areas, including restructuring, financings, claims management, mergers and acquisitions, post-acquisition integration, valuations, tax issues, and performance improvement. The Forensic and Litigation Consulting segment offers law firms, companies, government clients, and other interested parties with dispute advisory, investigations, forensic accounting, business intelligence assessments, and risk mitigation services. The Economic Consulting segment provides law firms, companies, government entities, and other interested parties with analysis of complex economic issues for use in legal and regulatory proceedings, strategic decision making, and public policy debates. The Technology segment offers electronic discovery and information management software services to companies, law firms, courts, and government agencies. This segments suite of software and services help clients locate, review, and produce electronically stored information, including e-mail, computer files, voicemail, instant messaging, and financial and transactional data. The Strategic Communications segment provides advice and consulting services relating to financial communications, brand communications, public affairs and reputation management, and business consulting. The company was founded in 1982 and is based in Baltimore, Maryland.

SOUTHERN COMPANY (THE) (NYSE:SO) - Southern Company, through its subsidiaries, operates as a utility company that provides electric service in the southeastern United States. The company generates, transmits, and distributes electricity through coal, nuclear, oil and gas, and hydro resources. It offers electric service primarily in Alabama, Georgia, Florida, and Mississippi; and serves approximately 4.4 million retail customers with approximately 42,000 megawatts of generating capacity. Southern Company also constructs, acquires, owns, and manages generation assets and sells electricity in the wholesale market. Its transmission assets include 27,000 miles of transmission lines and 3,400 substations. The company also provides digital wireless communications, such as push to talk, cellular service, text messaging, wireless Internet access, and wireless data to approximately 300,000 subscribers in the southeast; and wholesale fiber optic solutions to telecommunication providers under the name Southern Telecom. The company was founded in 1945 and is headquartered in Atlanta, Georgia.

MONOLITHIC POWER SYSTEMS, INC. (NASDAQ:MPWR) - Monolithic Power Systems, Inc. designs, develops, manufactures, and markets analog and mixed-signal semiconductors. It offers direct current (DC) to DC converter integrated circuits (IC) to convert and control voltages of various electronic systems, such as portable electronic devices, wireless LAN access points, computers, set top boxes, automobiles, and medical equipment. The company also provides lighting control ICs for systems that provide light source for liquid crystal display (LCD) panels in notebook computers, LCD monitors, car navigational systems, and LCD televisions. In addition, it offers audio amplifier ICs to amplify sound produced by audio processors; and class-D audio amplifiers for plasma televisions, LCD televisions, and DVD players. The company serves consumer electronics, communications, and computing markets. It sells its products through third party distributors and value-added resellers, as well as directly to original equipment manufacturers, original design manufacturers, and electronic manufacturing service providers. Monolithic Power Systems, Inc. was founded in 1997 and is headquartered in San Jose, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

Insider Trading tracks all insider trades and selects those insider buys that predict higher moves and insider sales that predict lower moves.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net